145 related articles for article (PubMed ID: 29434001)
21. New insights into the performance characteristics of the Planova-series hollow-fiber parvovirus filters using confocal and electron microscopy.
Nazem-Bokaee H; Chen D; O'Donnell SM; Zydney AL
Biotechnol Bioeng; 2019 Aug; 116(8):2010-2017. PubMed ID: 30982955
[TBL] [Abstract][Full Text] [Related]
22. Robustness of nanofiltration for increasing the viral safety margin of biological products.
Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
[TBL] [Abstract][Full Text] [Related]
23. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
24. Achieving high mass-throughput of therapeutic proteins through parvovirus retentive filters.
Bolton GR; Basha J; Lacasse DP
Biotechnol Prog; 2010; 26(6):1671-7. PubMed ID: 20859931
[TBL] [Abstract][Full Text] [Related]
25. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
26. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
27. Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.
Roth NJ; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gröner A; Gustafson M; Jorquera JI; Kreil TR; Misztela D; Moretti E; Moscardini M; Poelsler G; More J; Roberts P; Wieser A; Gajardo R
Transfusion; 2020 Nov; 60(11):2661-2674. PubMed ID: 32815181
[TBL] [Abstract][Full Text] [Related]
28. Removal of parvovirus B19 from hemoglobin solution by nanofiltration.
Abe H; Sugawara H; Hirayama J; Ihara H; Kato T; Ikeda H; Ikebuchi K
Artif Cells Blood Substit Immobil Biotechnol; 2000 Sep; 28(5):375-83. PubMed ID: 11009110
[TBL] [Abstract][Full Text] [Related]
29. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
Buchacher A; Iberer G
Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
[TBL] [Abstract][Full Text] [Related]
31. Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process.
Van Holten RW; Ciavarella D; Oulundsen G; Harmon F; Riester S
Vox Sang; 2002 Oct; 83(3):227-33. PubMed ID: 12366764
[TBL] [Abstract][Full Text] [Related]
32. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
33. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
34. Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy.
Jorquera JI
Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):17-21. PubMed ID: 19630865
[TBL] [Abstract][Full Text] [Related]
35. A novel approach to achieving modular retrovirus clearance for a parvovirus filter.
Stuckey J; Strauss D; Venkiteshwaran A; Gao J; Luo W; Quertinmont M; O'Donnell S; Chen D
Biotechnol Prog; 2014; 30(1):79-85. PubMed ID: 24123923
[TBL] [Abstract][Full Text] [Related]
36. Development of an intravenous immunoglobulin with improved safety and functional activity.
Roberts PL; Dolan T; Paddick M; Stagg S; More JE
Biologicals; 2015 Mar; 43(2):123-9. PubMed ID: 25498751
[TBL] [Abstract][Full Text] [Related]
37. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
[TBL] [Abstract][Full Text] [Related]
38. Virus removal capacity at varying ionic strength during nanofiltration of AlphaNine® SD.
Jorba N; Shitanishi KT; Winkler CJ; Herring SW
Biologicals; 2014 Sep; 42(5):290-3. PubMed ID: 24999080
[TBL] [Abstract][Full Text] [Related]
39. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
[TBL] [Abstract][Full Text] [Related]
40. Qualification of a novel inline spiking method for virus filter validation.
Lutz H; Chang W; Blandl T; Ramsey G; Parella J; Fisher J; Gefroh E
Biotechnol Prog; 2011; 27(1):121-8. PubMed ID: 20878721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
